Monocyte to HDL-Cholesterol ratio as an inflammation marker for ASCVDS
- VernacularTitle:Моноцит/их нягтлалт липопротейны холестеролын харьцаа нь зүрх судасны атеросклероз өвчний үрэвслийн маркер болох нь
- Author:
Ulziipagam U
1
;
Erdenebaatar B
1
;
Burmaa B
2
Author Information
1. Mongolian National University of Medical Science
2. School of Medicine
- Publication Type:Journal Article
- Keywords:
MHR-Monocyte/HDL cholesterol ratio;
ASCVD-Atherosclerotic cardiovascular disease
- From:Innovation
2020;14(2):62-66
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:Monocyte / High Density Lipoprotein Ratio (MHR) has become an inflammation
marker of atherosclerotic cardiovascular diseases and is a handy and reliable diagnostic marker
at a low cost.
Objectives:to suggest MHR as a new inflammation marker for ASCVDs by comparing it with other
risk factors of cardiovascular disease and assessing the significance in screening
Methods:This study conducted during October to December 2019 is a hospital-based cross
sectional study, with a total of 396 clients, all 20 to 64 years old, were selected as subjects of the
study using a certain criteria.
Results:78.47% of the male subjects and 34.31% of female subjects were diagnosed with
dislipidemia, which shows us that males were diagnosed more frequently. The study sample
consisted of 274 (72.87%) men and 102 (27.13%) women with mean age of 36.6±8.42 years (range,
20-64 years), 78.47% were male and 34.31% were females. 66.49% of total participants were newly
diagnosed with dyslipidemia. An age group of 30 to 40 years old were recorded with the highest
cases of dyslipidemia. Monocyte / High Density Lipoprotein Ratio (MHR) were 7.88 and 12.82 in
dyslipidemic and non-dyslipidemic subjects, respectively and showed that there is a statistically
significant difference(p<0.05). The 10-year ASCVD risk of 113 people aged 40-64 years, which
were classified in low risk group (<7.5%) and in high risk group (≥7.5%) were assessed by pooled
cohort equation and the results shows that risk percentage were 65.14% and 34.86% and there
is statistically significant difference in MHR, which were 10.58±4.80 and 14.07±4. 90 in respective
groups.
Conclusions:Prevalence of dyslipidemia in preventive screening were high in a group of 20-62
years old and the group of those were estimated high The 10-year ASCVD risk, also had relatively
higher MHR. Moreover, there is a positive relation between dyslipidemia and MHR. These results
show that it is possible to use MHR as a new inflammation marker in ASCVDs for early detection
purpose.
- Full text:Innovation-2020-14(2);62-66.pdf
